Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06189846
Other study ID # BCIA 2023/02
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 4, 2024
Est. completion date December 2024

Study information

Verified date December 2023
Source Bordeaux Colorectal Institute Academy
Contact Quentin DENOST, Prof
Phone +33 547501575
Email q.denost@bordeaux-colorectal-institute.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The objective of this prospective international cohort is to evaluate the LUMENEYE rectoscope for assessment on tumor response after total neoadjuvant treatment in rectal cancer. Patients included in this study will be patients who initially will be good candidates for organ preservation. The participating centers are all expert centers in tumor assessment. All patient assessments after neoadjuvant treatment for rectal adenocarcinoma will be included in each centre.


Description:

The recent validation of the Total Neoadjuvant Treatment (TNT) protocol and the improvement of techniques for evaluating tumor response are two major factors in the development of organ preservation in rectal cancer. Although recent publications have shown promising results of the two organ preservation strategies, Watch & Wait and Local excision, with a low oncological risk, some challenges remain to be addressed before the generalization of rectal preservation in clinical practice. Among these challenges, the improvement of patient selection and methods for evaluating tumor response appear necessary. The monitoring scheme for the tumor response has not yet been clearly established, but a 6 months programme of tumor response assessment has been recently published (Boubaddi EJSO 2023). Monitoring must consist of a clinical assessment (rectal examination and/or rectoscopy) and additional morphological examinations (rectal MRI) every two months. Tumor response after neoadjuvant treatment by MRI (TRG 1-5, Tumor Regression Grade) is established as a reliable method of tumor response assessment and accurate diagnosis of complete clinical response. However, discrepancies between clinical examination and radiological MRI may exist and patients undergoing watch-and-wait who develop local regrowth due to mistake in initial tumour response assessment are at higher risk for development of distant metastases (Sao Juliao DCR 2023) with a poor impact on long term oncological results. The development of the LumenEye digital rectoscope by the SurgEase company enables a comfortable and efficient scoping for the user and the patient (Lewis J BJGP Open 2022). With high quality images of Full HD images and video associated with a secure and connected intuitive software platform, this endoscope can have its place in the monitoring of tumor response. The contribution of this technology to the monitoring of the tumor response needs to be assessed. This medical device is CE marked and used in its intended purpose. The objective of this study is to evaluate the complete and/or nearly complete response with LumenEye digital rectoscope.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient = 18 years - Histologically confirmed diagnosis of adenocarcinoma of the rectum, - Patient who received radiotherapy and chemotherapy (TNT) or immunotherapy - Stage cT2T3 - cN0 or cN1 (= 3 positive LN or size = 8 mm) - no metastases - Baseline Tumour size = 5 cm (MRI) - Baseline Tumour = 8 from anal verge - Ability to consent. - Oral agreement after reading information letter Exclusion Criteria: - Tumour cT1 or cT4 - Baseline Tumour size > 5cm - Invaded external sphincter or levator muscle - Tumour cN2 (> 3 positive LN or size > 8 mm) - Metastasis - History of Inflammatory bowel disease - Patient with a history of pelvic radiotherapy or chemotherapy - Pregnant patients - Protected adults (individuals under guardianship by court order).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
International Cohort
Assessing tumour response following neoadjuvant treatment in rectal cancer include : Digital rectal examination Rectal MRI Rectoscopy ( Lumeneye device) The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment.

Locations

Country Name City State
France Clinique Tivoli-Ducos - Bordeaux Colorectal Institute Bordeaux
France Hôpital Européen de Marseille Marseille
France Hôpital Saint-Antoine - APHP Paris
France CHU de ROUEN Rouen
Italy Humanitas Research Hospital Milan
Netherlands Amsterdam UMC Amsterdam
Spain University Hospital Vall D'Hebron Barcelona
United Kingdom Imperial College London London

Sponsors (1)

Lead Sponsor Collaborator
Bordeaux Colorectal Institute Academy

Countries where clinical trial is conducted

France,  Italy,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of complete and/or nearly complete response To evaluate the complete and/or nearly complete response with LumenEye digital endoscopescope From 8 weeks to 24 weeks after the end of radiotherapy
Secondary Agreement for grading rectal tumour response between the endoscopic and MRI assessment of tumour response To evaluate the concordance between the endoscopic and MRI assessment of tumor response From 8 weeks to 24 weeks after the end of radiotherapy
Secondary Agreement for grading rectal tumour response between the clinical and endoscopic assessment of tumour response - To evaluate the concordance between the clinical and endoscopic assessment of tumor response. From 8 weeks to 24 weeks after the end of radiotherapy
Secondary Agreement for grading rectal tumour response between the clinical and MRI assessment of tumour response. To evaluate the concordance between the clinical and MRI assessment of tumor response. From 8 weeks to 24 weeks after the end of radiotherapy
Secondary Interobserver agreement for grading rectal tumour response using a digital rectoscope platform To assess the interobserver reproducibility of endoscopic response with LumenEye digital endoscope within 6 months after the end of neoadjuvant treatment. From 8 weeks to 24 weeks after the end of radiotherapy
Secondary Rate of changing attitude after using the digital rectoscope platform (intra-observer changing management). To evaluate the contribution of the digital ectoscope platform in the surgeon's decision-making From 8 weeks to 24 weeks after the end of radiotherapy
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A